Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI listens for warning signs of psychosis relapse

NCT ID NCT07397975

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether analyzing speech recordings with artificial intelligence can help predict when someone with psychosis might relapse. About 360 participants, including people with psychosis and healthy volunteers, will provide weekly voice samples and answer questions via a smartphone app over 12 months. The goal is to see if this approach is practical and accurate, laying groundwork for future tools that could alert doctors early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants at risk of relapse will be recruited from clinical settings while in a stable phase of partial or full remission. Depending on the site, eligible individuals may be either inpatients nearing discharge or outpatients under ongoing care. If the treating clinician considers the patient's mental state sufficiently stable, the study information and consent process may be initiated during inpatient care, prior to discharge. For outpatients, participants may be contacted by phone, or the study can be presented during routine outpatient or day clinic visits. Healthy participants will be recruited through community outreach, advertisements, and volunteer registries from universities and hospitals. healthy participants will be selected to match individuals with psychosis based on key characteristics such as age and sex in each site.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy participants Inclusion Criteria: * Between 18 and 65 years old. * Subjects must be able to provide informed consent (IC). * Participants must have provided signed informed consent prior to enrollment. * Participants should not take prescription drugs regularly. * Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish. * Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection. * Must be able to comply with the study schedule and procedures. Healthy participants Exclusion Criteria: * Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders). * Recreational drug use or psychiatric disorders due to use of alcohol. * Depression, anxiety, or other psychiatric disorders. * Family history of depression, anxiety, or other psychiatric disorders. * Individuals who are not able or willing to understand the purpose and details of the study. Individuals with psychosis Inclusion Criteria: * Between 18 and 65 years old. * Diagnoses include psychotic disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, psychosis not otherwise specified). * First visit must be during remission phase (baseline measurement). * Current positive symptoms rated 3 (mild) or lower on all of these Brief Psychiatric Symptom Scale (BPRS) items: hallucinatory behavior, unusual thought content, conceptual disorganization. * Must be able to comply with the study schedule and procedures. * Subjects must be able to provide IC. * Participants must have provided signed informed consent prior to enrollment. * Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish. * Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection. Individuals with psychosis Exclusion Criteria: * Severe comorbid speech disorders (aphasia or severe stuttering) that prevent adequate speech recording. * Individuals who are not able or willing to understand the purpose and details of the investigation. Citizens with psychiatric or somatic comorbidity, drug- or alcohol abuse will be allowed to participate, so that the sample will reflect the general population of citizens with psychosis and the study's endpoints will be generalizable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychotic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dokuz Eylul University

    NOT_YET_RECRUITING

    Izmir, Turkey (Türkiye)

  • National Institute of Mental Health

    NOT_YET_RECRUITING

    Klecany, 250 67, Czechia

  • Newcastle Hospital and RCSI University of Medicine and Health Sciences

    NOT_YET_RECRUITING

    Greystones, Wicklow, A63 CD30, Ireland

  • Psychiatric University Hospital Zurich and University of Zurich

    RECRUITING

    Zurich, 8032, Switzerland

  • The Arctic University of Norway

    ACTIVE_NOT_RECRUITING

    Tromsø, 9037, Norway

  • University Hospital Geneva and University of Geneva

    NOT_YET_RECRUITING

    Geneva, Chêne-Bourg, 1225, Switzerland

  • University Medical Center Groningen

    NOT_YET_RECRUITING

    Groningen, 9713, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.